双嘧达莫在实验性类风湿关节炎中的双重作用:经腺苷与AMPK通路抑制关节炎症并上调肌肉合成代谢
该研究在K/BxN诱导的小鼠类风湿关节炎模型中,预防性或治疗性给予双嘧达莫,评估其对关节炎症和类风湿性肌少症的作用。结果显示双嘧达莫可减轻关节、肌肉及全身炎症,并通过增加腺苷和AMP水平、激活A2BR及下游cAMP/AMPK信号、下调肌肉生长抑制素,对抗肌肉萎缩和活动减少。结论支持双嘧达莫在RA中兼具抗炎与促肌肉合成代谢的双重作用。
要点
- 双嘧达莫在K/BxN小鼠中减轻关节、肌肉和全身炎症。
- 双嘧达莫经腺苷/A2BR/cAMP/AMPK通路上调肌肉合成代谢。
- 该作用与下调肌肉生长抑制素表达相关,可对抗肌肉萎缩。
核心结论
- 双嘧达莫在实验性RA中具有双重作用:强效抗炎,以及经腺苷和AMPK信号介导、与肌肉生长抑制素相关的新型合成代谢作用。
研究设计与样本
- K/BxN诱导的小鼠接受每日预防性或治疗性双嘧达莫处理,于关节炎症高峰和缓解期处死。
- 研究包含运动活性测试、双能X线吸收测定、血清C反应蛋白分析、血清与肌肉细胞因子阵列、胫骨前肌与距骨关节组织学。
- 在腓肠肌中通过Western blot和逆转录聚合酶链反应分析肌生成、嘌呤能系统、萎缩和衰老关键标志物,并用高效液相色谱检测核苷酸含量。
- 采用C2C12细胞进行二维和三维模型实验。
主要发现
- 双嘧达莫减轻关节、肌肉和全身炎症,对抗肌肉萎缩和活动减少。
- 该合成代谢机制涉及肌肉生长抑制素表达下调。
- 效应由腺苷和AMP水平升高介导,激活腺苷A2BR及下游cAMP/AMPK信号通路。
临床怎么用
- 结果提示双嘧达莫可能作为RA及类风湿性肌少症的潜在治疗选择,但尚需临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Rheumatoid sarcopenia, characterized by the progressive loss of skeletal muscle mass and function, is a frequent comorbidity in rheumatoid arthritis (RA), linked to prolonged, severe systemic inflammation. Purinergic signaling (adenosine, AMP, and ATP) plays a crucial role in inflammation, myogenesis, and muscle hypertrophy. Dipyridamole, an antiplatelet agent, enhances extracellular adenosine availability, alters AMP/ATP ratio, and activates A2BR and AMP kinase (AMPK) pathways. We aim to investigate its potential use as a therapeutic agent for RA and rheumatoid sarcopenia. METHODS: K/BxN-induced mice received preventive or therapeutic dipyridamole treatment daily and were sacrificed at joint inflammation peak and resolution stage. Motor activity tests and dual-energy x-ray absorptiometry were performed. C-reactive protein levels were also analyzed in serum, and cytokines array was performed in serum and muscle. Histology of tibialis anterior and talus joint were studied. Myogenesis, purinergic system, atrophy, and senescence key markers were analyzed via Western blot and reverse transcriptase-polymerase chain reaction in gastrocnemius. Nucleotide content via high-performance liquid chromatography was performed. Two-dimensional and three-dimensional models with C2C12 cells were done. RESULTS: Dipyridamole reduced joint, muscle, and systemic inflammation, counteracting muscle wasting and physical inactivity via an anabolic mechanism involving down-regulation of myostatin expression. This effect was mediated by increased adenosine and AMP levels, which activate adenosine A2BR and downstream cAMP/AMPK signaling pathways. CONCLUSION: These results support a dual role for dipyridamole in RA, combining robust anti-inflammatory effects with a novel, myostatin-linked anabolic action on sarcopenia, mediated through adenosine and AMPK signaling, distinct from conventional therapeutic mechanisms.
引用
- Marco-Bonilla M, Fresnadillo M, Sanchez-Platero I, et al. Dual Action of Dipyridamole in Experimental Rheumatoid Arthritis: Suppression of Joint Inflammation and Upregulation of Muscle Anabolism via Adenosine and AMPK Pathways. Arthritis Rheumatol. 2026. PMID: 41466573. doi:10.1002/art.70047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。